admin, Author at EUGOGO

Does early response to intravenous glucocorticoids predict the final outcome in patients with moderate-to-severe and active Graves’ orbitopathy?

J Endocrinol Invest. 2017 May;40(5):547-553. doi: 10.1007/s40618-017-0608-z. Epub 2017 Feb 7. PubMed PMID: 28176220. Bartalena L, Veronesi G, Krassas GE, Wiersinga WM, Marcocci C, Marinò M, Salvi M, Daumerie C, Bournaud C, Stahl M, Sassi L, Azzolini C, Boboridis KG, Mourits MP, Soeters MR, Baldeschi L, Nardi M, Currò N, Boschi A, Bernard M, von Arx … Read more

Graves’ orbitopathy as a rare disease in Europe: a European Group on Graves’ Orbitopathy (EUGOGO) position statement.

Orphanet Journal of Rare Diseases 2017; 12:72 DOI 10.1186/s13023-017-0625-1 P. Perros, L. Hegedüs, L. Bartalena, C. Marcocci, GJ Kahaly, L Baldeschi, M. Salvi, JH Lazarus, A. Eckstein, S. Pitz, K. Boboridis, P. Anagnostis, G. Ayvaz, A. Boschi, TH Brix, N. Curro, O. Konuk, M. Marino, AL Mitchell, B. Stankovic, FB Törüner, G .von Arx, M. … Read more

Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves’ orbitopathy (MINGO): a randomised, observer-masked, multicentre trial.

Lancet Diabetes Endocrinol. 2018 Apr;6(4):287-298. doi: 10.1016/S2213-8587(18)30020-2. Epub 2018 Jan 31. PubMed PMID: 29396246. Kahaly GJ, Riedl M, König J, Pitz S, Ponto K, Diana T, Kampmann E, Kolbe E, Eckstein A, Moeller LC, Führer D, Salvi M, Curro N, Campi I, Covelli D, Leo M, Marinò M, Menconi F, Marcocci C, Bartalena L, Perros P, … Read more

Predictive score for the development or progression of Graves’ orbitopathy in patients with newly diagnosed Graves’ hyperthyroidism.

Eur J Endocrinol. 2018 Jun;178(6):635-643. doi: 10.1530/EJE-18-0039. Epub 2018 Apr 12. PMID: 29650691 W. Wiersinga, M. Zarkovic, L. Bartalena, S. Donati, P. Perros, O. Okosieme, D. Morris, N. Fichter, J. Lareida, G. von Arx, C. Daumerie, M. Buralcu, G. Kahaly, S. Pitz, B. Beleslin, J. Ciric, G. Ayvaz, O. Konuk, F. Törüner, M. Salvi, D. Covelli, N. Curro, … Read more

Asymmetry indicates worse disease in Graves’ Orbitopathy: results from a prospective cross-sectional multicentre study.

J Endocrinol Invest. 2020 Dec;43(12):1717-1722 P Perros, M Zarkovic et al. on behalf of the European Group on Graves’ Orbitopathy (EUGOGO).

The 2021 European Group on Graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy.

European Journal of Endocrinology. 2021;185(4):G43-G67. doi.org/10.1530/EJE-21-0479 L Bartalena, GJ Kahaly, L Baldeschi, CM Dayan, A Eckstein, C Marcocci, M Marinò, B Vaidya andWM Wiersinga on behalf of EUGOGO.

Presentation of Graves’ orbitopathy within European Group On Graves’ Orbitopathy (EUGOGO) centres from 2012 to 2019 (PREGO III)

Br J Ophthalmology. 2023;epub ahead of print: doi:10.1136/bjo-2022-322442 A Schuh, A Goksun, L Baldeschi, CR Hintschich et al. on behalf of EUGOGO.